Free shipping on all orders over $ 500

Enzastaurin

Cat. No. M1704
Enzastaurin Structure
Synonym:

LY317615

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 55  USD55 In stock
5mg USD 44  USD44 In stock
10mg USD 70  USD70 In stock
25mg USD 100  USD100 In stock
50mg USD 160  USD160 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Enzastaurin inhibits PKCβ, PKCα, PKCγ and PKCε with IC50's of 0.006, 0.039, 0.083 and 0.110 µM, respectively. Enzastaurin apparently inhibits tumor growth via multiple mechanisms: suppression of tumor cell proliferation, induction of tumor cell apoptosis and inhibition of tumor-induced angiogenesis.

Protocol (for reference only)
Cell Experiment
Cell lines PC-3 prostate cancer, HCT116 colon cancer, and U87MG glioblastoma cell lines
Preparation method Proliferation assays. Proliferation was assessed for all cell lines over a 6-day time course in media supplemented with 1% FBS (7 days total). Briefly, 1,000 cells were plated per well in a 96-well plate and changed to fresh media (1% FBS) with or without enzastaurin on days 1 and 4. On day 7, the media were removed and 100 μL propidium iodide (PI) solution (10 μg/mL in D-PBS) were added to each well. An initial reading for PI staining (excitation at 500 nmol/L, absorbance at 615 nmol/L) was done using the WallacVictor plate reader following a 30-minute incubation to determine the nonviable cell fraction. The plate was then frozen at −80 °C for 2 hours, thawed, and reread. The proliferative index was scored by subtracting the prefreeze data (nonviable cells) from the postfreeze data (all cells).
Concentrations 0~10µM
Incubation time 6 days
Animal Experiment
Animal models Athymic nude mice bearing HCT116 colon cancer xenografts
Formulation 10% acacia (Fisher Scientific, Fair Lawn, NJ) in water
Dosages twice daily at 75 mg/kg
Administration gavage
Chemical Information
Molecular Weight 515.61
Formula C32H29N5O2
CAS Number 170364-57-5
Solubility (25°C) DMSO 20 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Grønberg et al. Lung Cancer. A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.

[2] Ghobrial et al. Clin Cancer Res. A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenstrom Macroglobulinemia.

[3] Clément-Duchêne et al. Lung Cancer. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.

[4] Nwankwo et al. Invest New Drugs. Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.

[5] Cosenza et al. Ann Hematol. Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.

[6] Shimokawa et al. Br J Cancer. Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.

[7] Rampling et al. Neuro Oncol. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).

Related PKC Products
PKC β pseudosubstrate

PKC β pseudosubstrate is a selective cell-permeable inhibitor of PKC.

Protein Kinase C (19-31)

Protein Kinase C (19-31), a peptide inhibitor of protein kinase C (PKC), is used as protein kinase C substrate peptide for testing the protein kinase C activity.

Protein Kinase C (19-36)

Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC50 of 0.18 μM.

[Ala113]MBP(104-118)

[Ala113]MBP(104-118) is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC50s ranging from 28-62 μM.

[Ala107]MBP(104-118)

[Ala107]MBP(104-118) is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC50s ranging from 46-145 μM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Enzastaurin, LY317615 supplier, PKC, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.